Helix Biopharma Corp.
HBPCF
$1.71
-$0.02-1.16%
OTC PK
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.38M | 1.50M | 1.31M | 2.72M | 2.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.96M | 3.37M | 3.87M | 7.01M | 7.26M |
| Operating Income | -2.96M | -3.37M | -3.87M | -7.01M | -7.26M |
| Income Before Tax | -3.02M | -3.47M | -3.72M | -6.89M | -7.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.02 | -3.47 | -3.72 | -6.89 | -7.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.02M | -3.47M | -3.72M | -6.89M | -7.15M |
| EBIT | -2.96M | -3.37M | -3.87M | -7.01M | -7.26M |
| EBITDA | -2.96M | -3.36M | -3.86M | -7.00M | -7.25M |
| EPS Basic | -0.05 | -0.06 | -0.07 | -0.13 | -0.14 |
| Normalized Basic EPS | -0.03 | -0.04 | -0.04 | -0.08 | -0.09 |
| EPS Diluted | -0.05 | -0.06 | -0.07 | -0.13 | -0.14 |
| Normalized Diluted EPS | -0.03 | -0.04 | -0.04 | -0.08 | -0.09 |
| Average Basic Shares Outstanding | 276.18M | 249.87M | 223.02M | 204.26M | 193.85M |
| Average Diluted Shares Outstanding | 276.18M | 249.87M | 223.02M | 204.26M | 193.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |